Dr Reddy's Laboratories rose 2.91% to Rs 2,846.20 after the company said its board will meet on 27 March 2020 to consider raising funds through issuance of commercial papers.
On a consolidated basis, Dr Reddy's Laboratories reported a net loss of Rs 538.40 crore in Q3 December 2019 compared with a net profit of Rs 500.30 crore in Q3 December 2018. Net sales rose 13.9% to Rs 4,383.80 crore in Q3 December 2019 over Q3 December 2018.
Dr Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)